NCT03448744 is a Phase 4 clinical trial of Thymosin Alpha1 in Chronic Hepatitis b, sponsored by Wen-hong Zhang.

Who is sponsoring NCT03448744?

NCT03448744 is sponsored by Wen-hong Zhang.

What drugs are being tested in NCT03448744?

Interventions in NCT03448744: Thymosin Alpha1, Entecavir.

What condition does NCT03448744 study?

NCT03448744 studies Chronic Hepatitis b.

Is NCT03448744 still recruiting?

NCT03448744 is currently status unknown. Last updated 28 February 2018.

Last reviewed 2018-02-28 · How we verify

NCT03448744

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy and Safety of Combination Therapy of Thymalfasin and Entecavir in HBeAg-positive ETV-experienced Patients

Status unknown Phase 4 Last updated 28 February 2018

What this trial tests

Phase 4 trial testing Thymosin Alpha1 in Chronic Hepatitis b in 240 participants. Status unknown.

Timeline

25 October 2017

Primary endpoint
30 December 2018

30 December 2018

Quick facts

Lead sponsor	Wen-hong Zhang
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	240
Start date	25 October 2017
Primary completion	30 December 2018
Estimated completion	30 December 2018
Sites	1 location across China

Drugs / interventions tested

Thymosin Alpha1 — full drug profile →
Entecavir (ENTECAVIR) — full drug profile →

Conditions studied

Chronic Hepatitis b — all drugs for Chronic Hepatitis b →

Sponsor

Wen-hong Zhang — full company profile →

Who can join

Adults 18 to 55, any sex, with Chronic Hepatitis b. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a multicenter, randomized, open-label control trial of two arms conducted at 10 centres in China.The aim was to investigate whether sequential combination therapy with Thymosin alpha 1 and entecavir is superior to continuous ETV monotherapy in HBeAg-positive chronic hepatitis B patients with previous long-term entecavir therapy (≥ 2 years), and to select the optimal patients who may benefit from sequential combination therapy.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Development of Direct-acting Antiviral and Host-targeting Agents for Treatment of Hepatitis B Virus Infection.
Xia Y, Liang TJ. · · 2019 · cited 91× · PMID 30243618 · DOI 10.1053/j.gastro.2018.07.057

Verify or expand the search:

Other trials of Thymosin Alpha1

Trials testing the same drug.

NCT06598839 — Immuno-effect of Tα1 for Stage I NSCLC · NA · recruiting
NCT06139419 — The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for L · Phase 2 · active not recruiting
NCT05487469 — Thymosin α1 Use in Rheumatic Heart Disease Patients Undergoing Cardiac Surgery on Cardiopulmonary Bypass · NA · unknown
NCT04901104 — Long-term Prognosis of Patients With Sepsis After Immunotherapy · not yet recruiting
NCT05086614 — Thymosin-alpha 1 for Adjuvant Treatment After Radical Resection of High-risk Stage II and III Colorectal Cancer · Phase 3 · recruiting

Other recruiting trials for Chronic Hepatitis b

Currently open trials in the same condition.

NCT07090759 — To Evaluate the Efficacy, Safety and Population Pharmacokinetics of GST-HG141 in Patients With Chronic Hepatitis B (CHB) · Phase 3 · recruiting
NCT06989788 — A Study to Evaluate the Safety and Immunogenicity of an Investigational Vaccine for Chronic Hepatitis B Virus Infection, · Phase 1 · active not recruiting
NCT06885710 — HBV-Specific TCR-T Cell Therapy Combined With Nucleos(t)Ide Analogues in Chronic Hepatitis B Patients · Phase 1 · recruiting
NCT06671093 — Phase 1b, Open-label Study of Tune-401 to Assess Safety, PK and PD in Adults With Chronic Hepatitis B · Phase 1 · recruiting
NCT06638320 — Hepatitis Delta Virus Infection: Cross-sectional Study in Patients With Chronic Hepatitis B Virus Infection · active not recruiting

Other Wen-hong Zhang trials

Trials by the same sponsor.

NCT05965388 — Predictive Value of HBV pgRNA on Long-term Outcomes in Hepatitis B Patients Treated With Antiviral Therapy · not yet recruiting
NCT04946682 — Optimal Encephalitis/Meningitis Roadmap Via Precise Diagnosis and Treatment · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03448744 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Wen-hong Zhang
Last refreshed: 28 February 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03448744.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing